

27 November 2018

NSX Announcement

Extension of Settlement Date with Medicine Plus

Beroni Group Limited (NSX:BTG) (“Beroni” or “the Company”) wishes to advise that it has signed a variation deed with Medicine Plus Co., Ltd (“MP”) to extend the transaction settlement date to 30 April 2019 (or such other date as may be agreed between the Parties acting in good faith). Both parties also agreed to extend the terms of the previous extension announced on 21 September 2018 to the new settlement date.

For further information please contact:

Mr Jacky Zhang

Executive Chairman

Tel: +86 1851 6931 911

E: jacky.zhang@beronigroup.com

Mr Peter Wong

Executive Director and CFO

Tel: +61 423 727 580

E: peter.wong@beronigroup.com

About Beroni Group Limited (NSX:BTG)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences and environmental science industries.